A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
Gill H. et al, (2021), BLOOD, 138
Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN
Rodriguez-Meira A. et al, (2021), BLOOD, 138
The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Cross NCP. et al, (2021), Br J Haematol, 195, 338 - 351
CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
Palandri F. et al, (2021), HAEMATOLOGICA, 106, 5 - 6
THE BET INHIBITOR, CPI-0610, PROMOTES MYELOID DIFFERENTIATION IN MYELOFIBROSIS (MF) PATIENT BONE MARROW AND PERIPHERAL CD34+HEMATOPOIETIC STEM CELLS
Vannucchi A. et al, (2021), HAEMATOLOGICA, 106, 51 - 51
Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development.
Roy A. et al, (2021), Cell Rep, 36
Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia.
Iskander D. et al, (2021), Sci Transl Med, 13
Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Gupta V. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S362 - S362
CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: Update of MANIFEST phase 2 study
Platzbecker U. et al, (2021), ONCOLOGY RESEARCH AND TREATMENT, 44, 158 - 158
Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
Chowdhury O. et al, (2021), Br J Haematol, 194, 1010 - 1015
Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients
Mesa R. et al, (2021), CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21, S360 - S360
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm.
Salisbury RA. et al, (2021), Leukemia, 35, 2424 - 2430
Longitudinal and individual symptom analyses of momelotinib and ruxolitinib treated myelofibrosis patients from SIMPLIFY-1.
Mesa RA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Ahern DJ. et al, (2021)
Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.
Royston D. et al, (2021), Hematol Oncol Clin North Am, 35, 279 - 293
CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 96 - 96
Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients
Mead A. et al, (2021), BRITISH JOURNAL OF HAEMATOLOGY, 193, 101 - 102